Welcome to our dedicated page for NeuroBo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals stock.
NeuroBo Pharmaceuticals Inc. (NRBO), now MetaVia Inc., reports developments for a clinical-stage biotechnology business focused on cardiometabolic diseases. Its recurring company updates center on DA-1726, a dual oxyntomodulin analog agonist of GLP-1 and glucagon receptors for obesity, and DA-1241, an oral GPR119 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH.
News items commonly cover clinical trial data, dosing and formulation work, research collaborations, quarterly financial results, corporate presentations, investor-conference activity, and the completed corporate name change from NeuroBo to MetaVia. The updates connect the company's pipeline progress with cash runway commentary, partner relationships, and public-company communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.